Steven Bellon
Hoofd Techniek/Wetenschap/O&O bij FOGHORN THERAPEUTICS INC.
Vermogen: 899 335 $ op 30-04-2024
Actieve functies van Steven Bellon
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| FOGHORN THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 10-01-2022 | - |
| Corporate Officer/Principal | 01-06-2016 | 10-01-2022 |
Loopbaan van Steven Bellon
Eerdere bekende functies van Steven Bellon
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-09-2008 | 01-05-2016 |
| Corporate Officer/Principal | 01-09-2008 | 01-05-2016 |
Opleiding van Steven Bellon
| Haverford College | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Steven Bellon
- Ervaring
